Qiagen N.V. (FRA:QIA)
| Market Cap | 8.55B |
| Revenue (ttm) | 1.76B |
| Net Income (ttm) | 345.50M |
| Shares Out | n/a |
| EPS (ttm) | 1.65 |
| PE Ratio | 24.75 |
| Forward PE | 18.59 |
| Dividend | 1.42 (3.69%) |
| Ex-Dividend Date | Jul 2, 2025 |
| Volume | 8 |
| Average Volume | 925 |
| Open | 41.33 |
| Previous Close | 39.80 |
| Day's Range | 41.33 - 41.40 |
| 52-Week Range | 34.21 - 50.03 |
| Beta | n/a |
| RSI | 51.14 |
| Earnings Date | Feb 1, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial numbers in USD Financial StatementsNews
QGEN Crosses Above Key Moving Average Level
In trading on Monday, shares of Qiagen NV (Symbol: QGEN) crossed above their 200 day moving average of $45.61, changing hands as high as $46.49 per share. Qiagen NV shares are currently trading up abo...
QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a fast direc...
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to s...
Barclays Raises Price Target for QGEN to $55. ...
Barclays Raises Price Target for QGEN to $55.00 While Maintaining Overweight Rating | QGEN Stock News
Citigroup Downgrades QGEN, Lowers Price Target to $50.00 | QGEN Stock News
Citigroup Downgrades QGEN, Lowers Price Target to $50.00 | QGEN Stock News
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Qiagen N.V. (QGEN) Evercore 8th Annual Healthcare Conference December 3, 2025 10:50 AM ESTCompany ParticipantsRoland Sackers - CFO, MD & Member of...
Qiagen NV at Citi Global Healthcare Conference Transcript
Qiagen NV at Citi Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion - Slideshow
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 - Slideshow
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Wellington Management Group LLP Reduces Stake in Qiagen NV
Wellington Management Group LLP Reduces Stake in Qiagen NV
Qiagen N.V. 2025 Q3 - Results - Earnings Call Presentation
2025-11-14. The following slide deck was published by Qiagen N.V.
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, a...
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation o...
Seattle's Parse Biosciences to be acquired by Qiagen for $225M
Seattle's Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a $225 million cash
Relative Strength Alert For Qiagen
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Qiagen NV (QGEN) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Qiagen NV (QGEN) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Acquisitions Propel Future Outlook
Qiagen signals $2.38 adjusted EPS target and $500M share repurchase while advancing single-cell strategy
Discover Qiagen's Q3 2025 earnings call highlights: strong core growth, AI-driven Parse acquisition, raised EPS outlook, and major shareholder returns.
Qiagen N.V. (QGEN) Q3 2025 Earnings Call Transcript
Q3 2025 Qiagen NV Earnings Call Transcript
Q3 2025 Qiagen NV Earnings Call Transcript
Qiagen NV Q3 25 Earnings Conference Call At 9:30 AM ET
(RTTNews) - Qiagen NV (QGENF) will host a conference call at 9:30 AM ET on November 5, 2025, to discuss Q3 25 earnings results.
Qiagen NV Profit Rises In Q3
(RTTNews) - Qiagen NV (QGENF) on Tuesday reported third-quarter net income of $130 million or $0.60 per share, compared to $98 million or $0.44 per share last year.